Phathom Pharmaceuticals, Inc. (PHAT)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$180.9M
Cash & Equivalents
$15.7M
Quarterly Burn Rate
35 mo
Est. Cash Runway
$1,006M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (3 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
AMOXICILLIN, VONOPRAZAN FUMARATE
VOQUEZNA DUAL PAK |
APPROVED | Eosinophilic Esophagitis, Erosive Esophagitis, Gastric Cancer, Gastritis H Pylori, Gastroesophageal Reflux, Gastroesophageal Reflux Disease, H Pylori Gastritis, H Pylori Infection, Healthy Participants, Healthy Volunteers, Heartburn, Helicobacter Pylori Infection, Non-Erosive Gastro-Esophageal Reflux Disease, Symptomatic Non-erosive Gastroesophageal Reflux Disease, Symptomatic Nonerosive Gasroesophageal Reflux Disease |
|
VONOPRAZAN FUMARATE
VOQUEZNA |
APPROVED | — |
|
AMOXICILLIN, CLARITHROMYCIN, VONOPRAZAN FUMARATE
VOQUEZNA TRIPLE PAK |
APPROVED | — |
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-10-01 | Phase2 Readout | — |
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06660342 | A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring | OTHER | Recruiting | 728 |
| NCT06851559 | A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate V... | PHASE2 | Active Not Recruiting | 95 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.